Endocannabinoid system and pathophysiology of adipogenesis: Current management of obesity

Personalized Medicine

Volumn 4, Issue 3, 2007, Pages 307-319

  Iqbal, Omer ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adiponectin; Endocannabinoids; Insulin resistance; Metabolic syndrome; Peroxisome proliferator activated receptor; Polymorphism

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ADIPOCYTOKINE; ADIPONECTIN; ANANDAMIDE; ANDROSTANOLONE; BEZAFIBRATE; ENDOCANNABINOID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GHRELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEPTIN; MAGNESIUM; MURAGLITAZAR; NEBIVOLOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; RIMONABANT; UNINDEXED DRUG;

ADIPOCYTE; ADIPOGENESIS; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DECREASED APPETITE; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; EDEMA; ENDOCRINE FUNCTION; ENERGY METABOLISM; FOOD INTAKE; GENETIC POLYMORPHISM; HOMEOSTASIS; HORMONE SYNTHESIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE;

EID: 34548379390     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.4.3.307     Document Type: Review

References (133)

1. Flegal KM, Carrol MD, Ogden CL et al.: Prevalence and trends in obesity among US adults. 1990-2000. JAMA 288, 1723-1727 (2002).
2. Hedley AA, Ogden CL, Johnson CL et al: Prevalence of overweight and obesity among US children, adolescents and adults, 1992-2002. JAMA 291, 2847-2850 (2004).
3. Must A, Jacques PF, Dallal GE et al.: Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N. Engl. J. Med. 327, 1350-1355 (1992).
4. Kushner R, Roth J: Assessment of the obese patients. Endocrinol. Metab. Clin. North Am. 32, 915-933 (2003).
5. Daniels SR, Arnett DK, Eckel RH et al.: Overweight in children and adolescents: pathophysiology consequences, prevention and treatment. Circulation 111, 1999-2012 (2005).
6. Olshansky SJ, Pasarro DJ, Hershow RC et al.: A potential decline in life expectancy in the United States in the 21st century. N. Engl. J. Med. 352, 1138-1145 (2005).
7. US Department of Health and Human Services: The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity. Rockville, MD: US Department of Health and Human Services, Public Health Service, Office of Surgeon General, MD, USA (2001).
8. Gonthier MP, Hoareau L, Festy F et al.: Identification of endocannabinoids and related compounds in human fat cells. Obesity 15, 837-845 (2007).
9. Mechoulam R, Gaoni Y: Recent advances in the chemistry of Hashish. Fortschr. Chem. Org. Naturst. 25, 175-213 (1967).
10. di Marzo V, Fontana A: Anandamide, an endogenous cannabinomimetic eicosanoid: killing two birds with one stone. Prostaglandins Leukot. Essent. Fatty Acids 53, 1-11 (1995).
11. Matsuda LA, Lolait SJ, Brownstein MJ et al.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
12. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
13. Herkenham M, Lynn AB, Little MD et al.:Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci USA 87, 1932-1936 (1990).
14. Bensaid M, Gary-bobo M, Esclangon A et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63, 908-914 (2003).
15. Bonz A, Laser M, Kullmer S et al.: Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J. Cardiovasc. Pharmacol. 41, 657-664 (2003).
16. Liu J, Gao B, Mirshahi F et al.: Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346, 835-840 (2000).
17. Ishac EJ, Jiang L, Lake KD et al.: Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 118, 2023-2028 (1996).
18. Hannus L, Breuer A, Tchilibon S et al.: Hu-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl Acad. Sci. USA 96, 14228-14233 (1999).
19. Fride E, Foox A, Rosenberg E et al.: Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur. J. Pharmacol. 461, 27-34 (2003).
20. Okamoto Y, Morishita J, Tsuboi K et al.: Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem. 279, 5298-5305 (2003).
21. Giuffrida A, Beltramo M, Piomelli D: Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. 298, 7-14 (2001).
22. Varga K, Lake K, Martin BR et al.: Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 278, 279-283 (1995).
23. Niederhoffer N, Schmid K, Szabo B: The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiederbergs Arch. Pharmacol. 367, 434-443 (2003).
24. Huestis MA, Sampson AH, Holicky BJ et al.: Characterization of the absorption phase of marijuana smoking. Clin. Pharmacol. Ther. 52, 31-41 (1992).
25. Lake KD, Compton DR, Varga K et al.: Cannibinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther. 281, 1030-1037 (1997).
26. Bonowitz NL, Jones RT. Cardiovascular effects of prolonged 8-9-tetrahydrocannabinol ingestion. Clin. Pharmacol. Ther. 18, 287-297 (1975).
27. Wagner JA, Varga K, Ellis EF et al.: Activation of peripheral CB1 cannabinoid receptors in hemorrhagic shock. Nature 390, 518-521 (1997).
28. Wagner JA, Hu K, Bauersachs J et al.: Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. 38, 2048-2054 (2001).
29. Varga K, Wagner JA, Bridgen DK et al.: Platelet and macrophage-derived endogenous cannabinoid receptors are involved in endotoxin-induced hypotension. FASEB J. 12, 1035-1044 (1998).
30. Godlewski G, Malinoswska B, Schlicker E: Presynaptic cannabinoid CB (1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats. Br. J. Pharmacol. 142, 701-708 (2004).
31. Gerhardt CC, Romero IA, Cancello R et al.: Chemokine control fat accumulation and leptin secretion by cultured human adipocytes. Mol. Cell Endocrinol. 175, 81-92 (2001).
32. Braun JM, Lihn AS, Pedersen SB et al.: Monocyte chemotactic protein-1 release is higher in visceral than subcutaneous adipose tissue (AT): implication of macrophages resident in AT. J. Clin. Endocrinol. Metab. 90, 2282-2289 (2005).
33. Christiansen T, Richelsen B, Braun JM: Monocyte chemotactic protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. Metab. Disord. 29, 146-150 (2005).
34. Sartipy P, Loskutoff DJ: Monocyte chemotactic protein-1 in obesity and insulin resistance. Proc. Natl Acad. Sci. USA 100, 7265-7270 (2003).
35. Weisberg SP, Hunter D, Huber R et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 1, 115-124 (2006).
36. Chacon MR, Fernandez-Real JM, Richart C et al.: Monocyte chemoattractant protein-1 in obesity and Type 2 diabetes. Insulin sensitivity study. Obesity 15, 664-672, (2007).
37. Wellen KE, Hotamisiligil GS: Inflammation, stress and diabetes. J. Clin. Invest. 115, 1111-1119 (2005).
38. Rollins BJ: Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol. Med. Today 2, 198-204 (1996).
39. Linton MF, Fazio S: Macrophages, inflammation and atherosclerosis. Int. J. Obes. Rel. Metab. Disord. 27, S35-S40 (2003).
40. Cota D, Marsicano G, Tachop M et al.: The endogenous cannabinnoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423-431 (2003).
41. Cummings DE, Weigle DS, Frayo, RS et al.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346, 1623-1630 (2002).
42. Zieba DA, Amstalden M, Williams GL: Regulatory roles of leptin in reproduction and metabolism: a comparative review. Dom. Anim. Endocrinol. 29, 166 (2005).
43. Considine RV, Sinha MK, Heiman ML et al.: Serum immunoreactive leptin concentrations in normal weight and obese humans. N. Engl. J. Med. 334, 292-295 (1996).
44. Fruebis J, Tsao TS, Javorschi S et al.: Proteolytic cleavage of product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl Acad. Sci, USA 98, 2005-2010 (2005).
45. Gelfand EV, Cannon CP: Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J. Am. Coll. Cardiol. 47, 1919-1926 (2006).
46. Lafontan M: Fat cells: afferent and efferent messages define new approaches to treat obesity. Annu. Rev. Pharmacol. Toxicol. 45, 119-146 (2005).
47. Havel PJ: Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53(Suppl.), 143-151 (2004).
48. Arner P: The adipocyte in insulin resistance:key molecules and the impact of thiazolidinediones. Trends Endocrinol. Metab. 14, 137-145 (2003).
49. Lehmann JM, Moore LB, Smith-Oliver TA et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome-proliferators-activated receptor (PPAR ). J Biol. Chem. 270, 12953-12956 (1995).
50. Engeli S, Bohnke J, Feldpauscn M et al.: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54, 2838-2843 (2005).
51. Matias I, Gonthier M-P, Orlando P et al.: Regulation, function, and dysregulation, of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91, 3171-3180 (2006).
52. Fu J, Gaetani S, Oveisi F et al.: Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425, 90-93 (2003).
53. Guzman M, Lo Verme J, Fu J et al.: Oleylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferators-activated receptor α (PPAR α). J. Biol. Chem. 279, 27849-27854 (2004).
54. Lo Verme J, Fu J, Astarita G et al.: The nuclear receptor peroxisome proliferators-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15-19 (2005).
55. Darmani NA, Izzo AA, Degenhardt B et al.: Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48, 1154-1163 (2005).
56. Gladzicki D, Muller-Vahl K, Sturhrmann M: A frequent polymorphism in the coding exon of human cannabinoid receptor (CNR1) gene. Mol. Cell Probes 13, 321-323 (1999).
57. Zhang PW, Ishiguro, H, Ohtsuki T et al.: Human cannabinoid receptor 1:5 exons, candidate regulatory regions, polymorphism, haplotypes and association with polysubstance abuse. Mol. Psychiatry 916-931 (2004)
58. Russo P, Strazzullo P, Cappuccio, FP et al.: Genetic variations at the endo cannaboid Type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J. Clin. Endocrinol. Metab. 92 (6), 2382-2386 (2007).
59. Dawson E: Identification of a polymorphic triplet marker for the brain cannabinoid receptor gene: use in linkage and association studies of schizophrenia. Psychiatr. Genet, 5, S50 (1995).
60. Aberle J, Fedderwitz I, Klages N, George E, Beil FU: Genetic variation in two proteins of the endocannabinoid system and their influence on body mass index and metabolism under low fat diet. Horm. Metab. Res. 39, 395 (2007).
61. Gazzerro P, Caruso MG, Notarnicola M et al.: Association between cannabinoid type-1 receptor polymorphism, and body mass index in a southern Italian population. Int. J. Obes., (Lond.) 31, 908 (2007).
62. Sipe JC, Waalen J, Gerber A et al.: Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase. Int. J. Obes. (Lond.) 29, 755 (2005).
63. Matias I, Gonthier MP, Orlando P et al.: Regulation, function and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J. Clin. Endocrinol. Metab. 91, 3171-3180 (2006).
64. Osie-Hyiaman D, DePetrillo M, Pacher P et al.: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115:1298-1305 (2005).
65. Rinaldi-Carmona M, Barth F, Heaulm M et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350, 240-244 (1994).
66. Meier U, Gressner AM: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin. Chem. 50, 1511-1525 (2004).
67. Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 6, 772-783 (2006).
68. Engl J, Bobbert T, Ciardi C et al.: Effects of pronounced weight loss on adiponectin oligomer composition and metabolic parameters. Obesity 15, 1172-1178 (2007).
69. Arita Y, Kihara S, Ouchi N et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83 (1999).
70. Lara-Castro C, Luo N, Wallace P et al.: Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes, 55, 249-259 (2006).
71. Bobbert T, Roschlitz H, Wegewitz U et al.: Changes of adiponectin oligomer composition by moderate weight reduction. Diabetes 54, 2712-2719 (2005).
72. Chen H, Montagnani M, Funahashi T et al.: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 278, 45021-45026 (2003).
73. Ouchi N, Kihara S, Arita Y et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein. Circulation 100, 2473-2476 (1999).
74. Ouchi N, Kihara S, Arita Y et al.: Adiponectin, adipocyte-derived plasma protein, inhibits endothelial NF-kB signaling through CAMP-dependent pathway. Circulation 102, 1296-1301 (2000).
75. Fasshauer M, Kralisch S, Klier M et al.: Adiponectin gene expression and secretion is inhibited by interieukin-6 in 3T3-L1 adipocytes. Biochem. Biophy. Res. Commun. 301, 1045-1050 (2003).
76. Berg AH, Combs TP, Du X et al.: The adipocyte secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7, 947-953 (2001).
77. Fasshauer M, Klein J, Neumann S et al.: Adiponectin gene expression is inhibited by beta adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 507, 142-146 (2001).
78. Celik T, Iyisoy A. Kursaklioglu H et al.: Comparative effects of nebivolol and metaprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J. Hypertens. 24, 591-596b (2006).
79. Alexis Biochemicals: Adipokines and related products. Product Newsletter, March (2006).
80. Orci L, Cook WS, Ravazzola M et al.: Rapid transformation of white adipocytes into fat oxidizing machines. Proc. Natl. Acad. Sci. USA 101, 2058-2063 (2004).
81. Tataranni PA, Ortega E: A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on Type 2 diabetes? Diabetes 54, 917-927 (2005).
82. Bo S, Gentile L, Ciccone G et al.: The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern European population-based cohort. Diabetis Metab. Res. Rev. 21, 515-524 (2005).
83. Ye X, Yu Z, Li H et al.: Distribution of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J. Am. Coll. Cardiol. 49, 1798-1805 (2007).
84. Chacon MR, Fernandez-Real JM, Richart C et al.: Monocyte chemotactic protein-1 in obesity and Type 2 diabetes. Insulin sensitivity study. Obesity 15, 664-672 (2007).
85. Linton MF, Fazio S: Macrophages, inflammation, and atherosclerosis. Int. J. Obes. Rel. Metab. Disord. 27, S35-S40 (2003).
86. Weisberg SP, Hunter D, Huber R et al.: CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin. Invest. 1, 115-124 (2006).
87. Gilde AJ, Fruchart J-C, Staels B: Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease. J. Am. Coll. Cardiol. 48, A24-A32 (2006).
88. Auwers J. Schoonjans K, Fruchart JC et al.: Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherioclerosis 124(Suppl.), S29-S37 (1996).
89. Issermann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferation. Nature 347, 645-650, (1990).
90. Mukherjee R, Jow L, Noonan D et al.: Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J. Steroid Biochem. Mol. Biol. 51, 157-166 (1994).
91. Ausboeuf D. Riesseut J, Fajas L et al.: Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X-receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319-1327 (1997).
92. Escher P, Braissant O, Basu-Modak S et al.: Rat PPARs; quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142, 4195-4202 (2001).
93. Krey G, Braissant O, L'Horset F et al.: Fatty acids and eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptor ligand assay. Mol. Endocrinol. 11, 779-791 (1997).
94. Kliewer SA, Sundseth SS, Jones SA et al.: Fatty acids and eicosanoids, regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad Sci. USA 94, 4318-4323 (1997).
95. Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl Acad. Sci. USA 94, 4312-4317 (1997).
96. Staels B, Koenig W, Habib A et al.: Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790-793 (1998).
97. Chinetti-Ghagiudi G, Fruchart JC, Staels B et al.: Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostatic new approaches to therapy. Curr. Opin. Pharmacol. 5, 177-183 (2005).
98. Schoonjans K, Staels B, Auwers J: Role pf peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid. Res. 37, 907-925 (2000).
99. Staels B, Dallonevine J, Auwers J et al.: Mechanism of action of fibrate on lipid and lipoprotein metabolism. Circulation. 98, 2088-2093 (1998).
100. Kliewer SA, Lehmann JM, Wilson TM: Orphan nuclear receptors: shifting endocrinology into reverse. Science 30, 757-760 (1999).
101. Bourgeois F, Alexiu A, Lemonnier D: Dietary-induced obesity effect of dietary fats on adipose tissue cellularity in mice. Br. J. Nutr. 49, 17-26 (1983).
102. Costet P, Legendre C, Mone J et al.: Peroxisome-proliferator activated α-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J. Biol. Chem. 273, 29577-29585 (1998).
103. Chaput E, Saladin R, Silvestre M et al.: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem. Biophys. Res. Commun. 271, 445-450 (2000).
104. Jones PA, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95, 120-122 (2005).
105. Davidson MH: Controversy surrounding the safety of cerivastatin. Expert Opin. Drug Saf., 1, 207-212 (2002).
106. Thomson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 289, 1681-1690 (2003).
107. Berger J, Leibowitz MD, Doebber TW et al.: Novel Peroxisome proliferator-activated receptor (PPAR) and RPARδ ligands produce distinct biological effects. J. Biol. Chem. 274, 6718-6725 (1999).
108. Oliver WR Jr, Shenk JL, Snaith MR et al.: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl Acad. Sci. USA 98, 5306-5311 (2001).
109. Leibowitz MD, Fievet C, Hennuyer N et al.: Activation of PPAR δ alters lipid metabolism in db/db mice. FEBS Lett. 473, 333-336 (2000).
110. Luquet S, Lopez-Soriano J, Holst D et al.: Peroxisome proliferator-activated receptor delta controls muscle development and oxidative capability. FASEB J 17, 2299-2301 (2003).
111. Moller DE, Berger JP: Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int. J. Obes. Rel. Metab. Disord. 27(Suppl. 3), S17-S21 (2003).
112. Yki-Jarvinen H: Thiazolidinediones. N. Engl. J. Med. 351, 1106-1118 (2004).
113. Staels B: PPARγ and atherosclerosis. Curr. Med. Res. Opin. 21(Suppl. 1), S13-S20. (2005).
114. Marx N, Froehlich J, Siam L et al.: Antidiabetic PPARγ activator rosiglitazone reduces MMP-9 serum levels in Type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23, 283-288 (2003).
115. Marz N, Imhof A, Froehlich J et al.: Effect of rosiglitazone treatment on soluble CD40L in patients with Type 2 diabetes and coronary artery disease. Circulation 107, 1954-1957 (2003).
116. Pfutzner A, Marx N, Lubben G et al.: Improvement of cardiovascular risk markers by pioglitazone is independent from glycaemic control: results from the pioneer study. J. Am. Coll. Cardiol. 45, 1925-1931 (2005).
117. Sidhu JS, Cowan D, Kaski JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, on markers of endopthelial activation, C-reactive protein and fibrinogen levels in non-diabetic coronary artery disease patients. J. Am. Coll. Cardiol. 42, 1757-1763 (2003).
118. Zhang H, Zhang A, Kohan DE et al.: Collecting duct specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc. Natl Acad. Sci. USA 102, 9406-9411 (2005).
119. Dormansdy JA, Charbonnel B, Eckland DH et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective Pioglitazone Clinical Trial in Macrovascular Events): a randomized controlled trial. Lancet 366, 1279-1289 (2005).
120. Adamo KB, Dent R, Langefield CD et al.: Peroxisome proliferator-activated receptor γ2 and Acy-CoA synthetase 5 polymorphisms influence diet response. Obesity 15, 1068-1075 (2007).
121. Zeggini E, Parkinson JR, Halford S et al.: Examining relationships between the Pro12ala variant in PPARG and Type 2 diabetes-related traits in UK samples. Diabet. Med. 22, 1696-1700 (2005).
122. Muller YL, Bogardus C, Beamer BA et al.: A functional variant in the peroxisome proliferator-activated receptor γ2 promoter is associated with predictors of obesity and Type 2 diabetes in Pima Indians. Diabetes 52, 1864-1871 (2003).
123. Lohmueller et al.: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33, 177 (2003).
124. Flavell DM, Pineda Totta I, Jamshidi Y et al.: Variation in PPARα gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetes subjects. Diabetalogia 43, 673-680 (2000).
125. Finck BN, Barnal-Mizrachi C, Han DH et al.: A potential link between muscle peroxisome proliferator activated receptor α signaling and obesity-related diabetes. Cell Metab. 1, 133-144 (2005).
126. Skogsberg J, Kannisto K, Cassel TN et al.: Evidence that peroxisome proliferator-activated receptor δ influences cholesterol metabolism in men. Arterioscler. Thromb. Vasc. Biol. 23, 637-643 (2003).
127. Ludovico O, Pellegrini F, di Poola R et al.: Heterogeneous effect of peroxisome proliferator-activated receptor γ2 Ala12 variant on Type 2 diabetes risk. Obesity 15, 1076-1081 (2007).
128. Leidy HJ, Dougherty KA, Frye BR et al.: Twenty-four-hour ghrelin is elevated after calorie restriction and exercise training in non-obese women. Obesity 15, 446-455 (2007).
129. Ford ES, Li C, McGuire LC et al.: Intake of dietary magnesium and the prevalence of the metabolic syndrome among US adults. Obesity 15, 1139-1146 (2007).
130. Guerrero-Romero F, Rodriguez-Moran M: Low serum magnesium levels and metabolic syndrome. Acta Diabetol. 39, 209-213 (2002).
131. Bolduc C, Yoshioka M, St-Amand J: Transcriptomic characterization of the long-term dihydrtesterone effects in adipose tissue. Obesity 15, 1107-1132 (2007).
132. Iqbal O, Fareed J: Clinical applications of bioinformatics, genomics, and pharmacogenomics. In: Methods in Molecular Biology Vol. 316, Bioinformatics and Drug Discovery. Larson RS (Ed.), Humana Press Inc., NJ, USA, 159-178 (2006).
133. Jeong S, Yoon M: Inhibition of the actions of peroxisome proliferator-activated receptor-α on obesity by estrogen. Obesity 15(6), 1430-1440 (2007).